Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004263 | 0.95 | IGF1R (0.58) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3013881 | 0.89 | IGF1R (0.54) | IGF1RCDK2CCNE2CCNE1SRC | |
| SCHEMBL3013381 | 0.89 | IGF1R (0.58) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL13226221 | 0.89 | IGF1R (0.51) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL3009241 | 0.89 | IGF1R (0.53) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3005974 | 0.89 | IGF1R (0.53) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3013423 | 0.89 | IGF1R (0.53) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3011992 | 0.88 | IGF1R (0.51) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3011423 | 0.88 | IGF1R (0.52) | IGF1RCDK2CCNE2CCNE1HPGDS | |
| SCHEMBL3013720 | 0.88 | IGF1R (0.52) | IGF1RCDK2CCNE2CCNE1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| WO-2009015254-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | ABL1, STK25, FLT3 | IGF1R 688/4885CDK2 108/4885CCNE2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.